非小细胞肺癌中LAG-3蛋白表达及其与PD-1/PD-L1和肿瘤浸润淋巴细胞的关系
研究评估了55种NSCLC细胞系及139例手术切除标本中LAG-3、PD-1、PD-L1表达与TILs丰度,并在62例未治疗NSCLC中验证。LAG-3在部分患者TILs表达(25.9%),非腺癌高于腺癌,与PD-1/PD-L1相关;LAG-3阳性与术后早期复发及较差预后相关,与EGFR/KRAS/ALK无关联。
要点
- LAG-3在36例(25.9%)NSCLC患者TILs表达,肿瘤细胞不表达。
- LAG-3在TILs的表达非腺癌高于腺癌(p=0.031)。
- LAG-3阳性TILs患者无复发生存和总生存均较短,与不良预后相关。
核心结论
- LAG-3在部分NSCLC患者肿瘤组织的TILs上表达,非腺癌中更高,且与PD-1/PD-L1表达相关。
- LAG-3阳性或LAG-3与PD-L1双阳性与术后早期复发相关,LAG-3与不良预后相关。
研究设计与样本
- 研究评估55种NSCLC细胞系中LAG-3蛋白表达(免疫组化,EPR4392 [Abcam, Cambridge, MA])。
- 在139例手术切除的NSCLC标本中免疫组化评估LAG-3、PD-1(NAT 105 [Cell Marque, Rocklin, CA])、PD-L1(22C3 [Dako, Carpenteria, CA])表达并评分TILs丰度。
- 在62例未经治疗的NSCLC患者样本中验证结果,并检测LAG-3表达与EGFR、KRAS突变及EML4-ALK重排的相关性。
主要发现
- 55种NSCLC细胞系均未表达LAG-3;肿瘤细胞不表达LAG-3和PD-1。
- 139例手术标本中,36例(25.9%)TILs表达LAG-3,60例(43.2%)TILs PD-1阳性,25例(18.0%)肿瘤细胞PD-L1阳性。
- LAG-3在TILs的表达非腺癌高于腺癌(p=0.031)。
- TILs LAG-3表达与TILs PD-1(p<0.001)及肿瘤细胞PD-L1(p=0.041)显著相关,与TIL百分比无关(p=0.244)。
- logistic回归中,非腺癌对比腺癌的LAG-3 OR为0.320(95%CI 0.110-0.929),PD-1阴性对比阳性TILs的OR为4.364(95%CI 1.898-10.031)。
关键数值与推荐
- TILs LAG-3阴性对比阳性患者无复发生存为1.91年(95%CI 0.76-3.06)对0.87年(95%CI 0.27-1.47)(p=0.025)。
- TILs LAG-3阴性对比阳性患者总生存为3.04年(95%CI 2.76-3.32)对1.08年(95%CI 0.42-1.74)(p=0.039)。
- PD-L1阴性肿瘤细胞且LAG-3阴性TILs患者无复发生存2.09年(95%CI 0.90-3.28),PD-L1或LAG-3阳性者1.42年(95%CI 0.46-2.34),双阳性者0.67年(95%CI 0.00-1.45)(p=0.007)。
- 验证阶段,LAG-3高表达与TILs PD-1高表达(p=0.016)及肿瘤细胞PD-L1高表达(p=0.014)显著相关。
- LAG-3表达与EGFR(p=0.325)、KRAS突变(p=1.000)及ALK融合(p=0.562)无相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunotherapy targeting the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint has shown promising efficacy in patients with NSCLC. Lymphocyte activating 3 gene (LAG-3) is another important checkpoint, and its role in NSCLC is still not clear. In this study we investigated lymphocyte activing 3 (LAG-3) protein expression; its correlation with PD-1, PD-L1, and tumor-infiltrating lymphocytes (TILs); and its association with survival in NSCLC. METHODS: The expression of LAG-3 (EPR4392 [Abcam, Cambridge, MA]) protein was assessed in 55 NSCLC cell lines by immunohistochemistry. LAG-3, PD-1 (NAT 105 [Cell Marque, Rocklin, CA]), and PD-L1 (22C3 [Dako, Carpenteria, CA]) protein expression was evaluated by immunohistochemistry, and TIL abundance was scored in 139 surgically resected specimens from patients with NSCLC. We also verified results in samples from 62 patients with untreated NSCLC and detected a correlation between LAG-3 expression and EGFR and KRAS mutation and echinoderm microtubule associated protein like 4 gene (EML4)-anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement. RESULTS: LAG-3 was not expressed on any of the 55 NSCLC cell lines. However, LAG-3 was expressed on the TILs in 36 patients with NSCLC (25.9%). Sixty patient samples (43.2%) were positive for PD-1 on the TILs, and 25 (18.0%) were positive for PD-L1 on tumor cells. Neither LAG-3 nor PD-1 was expressed on the tumor cells. LAG-3 was overexpressed on the TILs in nonadenocarcinoma compared with in adenocarcinoma (p = 0.031). LAG-3 expression on TILs was significantly correlated with that of PD-1 on TILs (p < 0.001) and PD-L1 on tumor cells (p = 0.041) but not with TIL percentage (p = 0.244). With the logistic regression model, the ORs for LAG-3 were 0.320 (95% confidence interval [CI]: 0.110-0.929) and 4.364 (95% CI: 1.898-10.031) when nonadenocarcinoma was compared with adenocarcinoma and TILs that were negative for PD-1 were compared with those positive for PD-1. Recurrence-free survival was significantly different in patients whose TILs were LAG-3-negative as opposed to LAG-3-positive (1.91 years [95% CI: 0.76-3.06] versus 0.87 years [95% CI: 0.27-1.47] [p = 0.025]). Likewise, LAG-3 status of TILs (negative versus positive) did significantly affect overall survival (OS) (3.04 years [95% CI: 2.76-3.32] versus 1.08 years [95% CI: 0.42-1.74] [p = 0.039]). Using Kaplan-Meier analysis, we found that patients with both PD-L1-negative tumor cells and LAG-3-negative TILs have longer recurrence-free survival than patients who are either PD-L1- or LAG-3-positive or both PD-L1- and LAG-3-positive (2.09 years [95% CI: 0.90-3.28] versus 1.42 years [95% CI: 0.46-2.34] versus 0.67 years [95% CI: 0.00-1.45] [p = 0.007]). In the verification stage, high expression of LAG-3 was also significantly correlated with higher expression of PD-1 on TILs (p = 0.016) and PD-L1 on tumor cells (p = 0.014). There was no correlation between LAG-3 expression and EGFR (p = 0.325) and KRAS mutation (p = 1.000) and ALK fusion (p = 0.562). CONCLUSIONS: LAG-3 is expressed on TILs in tumor tissues of some patients with NSCLC. Its expression was higher in nonadenocarcinoma and correlated with PD-1/PD-L1 expression. LAG-3 positivity or both LAG-3 and PD-L1 positivity was correlated with early postoperative recurrence. LAG-3 was related to poor prognosis.
引用
- He Y, Yu H, Rozeboom L, et al. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017. PMID: 28132868. doi:10.1016/j.jtho.2017.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。